Dopamine is released from the presynaptic terminal, diffuses over the synaptic cleft and activates Dopaminergic receptors (D1-D5 receptors). After release from the nerve terminal, Dopamine is taken up via a presynaptically located Dopamine transporter and degraded by the Mono amine oxidase B (MAO-B).

file_download Download in HQ
Published 10.05.2016
Permissions
Published 10.05.2016
Permissions

Related content

grid_view Slide Deck
Parkinson’s Disease – Epidemiology and Burden
08.02.2025 Parkinson’s Disease
image Image
Trajectories of neurodegeneration in body- and brain-first subtypes of Lewy body disease

In brain-first patients (bottom panel), the dopamine system starts to degenerate early

23.01.2025 Parkinson’s Disease
image Image Characteristics of proposed body-first and brain-first subtypes of PD. Arrows indicate the direction of spread of α-synuclein pathology. In body-first Parkinson disease (left), the first α-synuclein aggregation occurs in the gut and propagates through the sympathetic nervous system to the sympathetic trunk and heart, and via the vagus nerve to the brainstem. Autonomic dysfunction and REM sleep behaviour disorder (RBD) are prodromal features. In brain-first PD (right), the initial α-synuclein pathology enters via the olfactory bulb (OB) and spreads to the amygdala and nigrostriatal dopamine system. The pathology then descends through the brainstem and RBD and dysautonomia generally develop after the onset of parkinsonism. During the later disease stages, nearly all patients have widespread pathology in these systems and their symptomatology therefore converges.
Body-first vs brain-first Lewy Body Disease

Characteristics of proposed body-first and brain-first subtypes of Parkinson’s disease

23.01.2025 Parkinson’s Disease